Presented by a member of our Ad Board Dr Michael Reardon. The advocates we have are so high profile. It’s a real credit to our science.
"TAVR has revolutionized the treatment of aortic stenosis with more TAVR cases now performed than surgical aortic valve replacement for this disease,” said Michael Reardon, principal investigator for the trial, which was presented during a late-breaking session at this year's annual Transcatheter Cardiovascular Therapeutics conference.
TCT conference starts tomorrow, page-32
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.40 |
Change
-0.290(1.55%) |
Mkt cap ! $353.6M | |||
| Open | High | Low | Value | Volume |
| $18.70 | $18.70 | $18.20 | $96.48K | 5.231K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $18.30 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.40 | 52 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |